Arthritis drug tested to tame Life-Threatening CAR-T side effects
NCT ID NCT04359784
Summary
This study tested if a drug called anakinra could prevent two serious and potentially life-threatening side effects—cytokine release syndrome (CRS) and neurotoxicity—in patients with B-cell lymphoma receiving CAR-T cell therapy. Twenty-seven adult patients received anakinra alongside their standard CAR-T treatment. The goal was to see if this approach could make the powerful cancer therapy safer by controlling its severe inflammatory side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.